Cancer Clinical Trial -Caribou Biosciences - CB10A

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma

Drug

CB-010, Cyclophosphamide, Fludarabine

Phase

Phase I

Condition

Lymphoma, Non-Hodgkin Relapsed, Non Hodgkin Lymphoma Refractory, B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma B Cell, Lymphoma B Cell Non-Hodgkin's Lymphoma

Keywords

Lymphoma, Non-Hodgkin Lymphoma, B-Cell